View in EDS

Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial.

Saved in:
Bibliographic Details
Title: Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial.
Authors: Craig T; Allergy, Asthma and Immunology, Department of Medicine and Pediatrics, Penn State University, Hershey, PA, USA. Electronic address: tcraig@pennstatehealth.psu.edu., Magerl M; Institute of Allergology, Charité-Universitätsmedizin Berlin, Berlin, Germany., Levy DS; Division of Allergy and Immunology, University of California, Irvine, CA, USA., Reshef A; Allergy, Immunology and Angioedema Center, Barzilai University Hospital, Ashkelon, Israel., Lumry WR; AARA Research Center, Dallas, TX, USA., Martinez-Saguer I; HZRM Haemophilia Center Rhein Main, Mörfelden-Walldorf, Germany., Jacobs JS; Allergy and Asthma Clinical Research, Walnut Creek, CA, USA., Yang WH; Ottawa Allergy Research Corporation, Department of Medicine, University of Ottawa, Ottawa, ON, Canada., Ritchie B; Division of Hematology, Department of Medicine, University of Alberta, Edmonton, AB, Canada., Aygören-Pürsün E; Department of Children and Adolescents, University Hospital Frankfurt, Goethe University, Frankfurt, Germany., Keith PK; McMaster University Medical Centre Site, Hamilton, ON, Canada., Busse P; Division of Clinical Immunology and Allergy, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Feuersenger H; CSL Behring Innovation GmbH, Marburg, Germany., Pawaskar D; CSL Behring, King of Prussia, PA, USA; Janssen Research & Development LLC, Spring House, PA, USA., Jacobs I; CSL Behring, King of Prussia, PA, USA., Pragst I; CSL Behring Innovation GmbH, Marburg, Germany., Doyle MK; CSL Behring, King of Prussia, PA, USA; Aro Biotherapeutics, Philadelphia, PA, USA.
Source: Lancet (London, England) [Lancet] 2022 Mar 05; Vol. 399 (10328), pp. 945-955. Date of Electronic Publication: 2022 Feb 24.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35219377
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Craig+T%22">Craig T</searchLink>; Allergy, Asthma and Immunology, Department of Medicine and Pediatrics, Penn State University, Hershey, PA, USA. Electronic address: tcraig@pennstatehealth.psu.edu.<br /><searchLink fieldCode="AU" term="%22Magerl+M%22">Magerl M</searchLink>; Institute of Allergology, Charité-Universitätsmedizin Berlin, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Levy+DS%22">Levy DS</searchLink>; Division of Allergy and Immunology, University of California, Irvine, CA, USA.<br /><searchLink fieldCode="AU" term="%22Reshef+A%22">Reshef A</searchLink>; Allergy, Immunology and Angioedema Center, Barzilai University Hospital, Ashkelon, Israel.<br /><searchLink fieldCode="AU" term="%22Lumry+WR%22">Lumry WR</searchLink>; AARA Research Center, Dallas, TX, USA.<br /><searchLink fieldCode="AU" term="%22Martinez-Saguer+I%22">Martinez-Saguer I</searchLink>; HZRM Haemophilia Center Rhein Main, Mörfelden-Walldorf, Germany.<br /><searchLink fieldCode="AU" term="%22Jacobs+JS%22">Jacobs JS</searchLink>; Allergy and Asthma Clinical Research, Walnut Creek, CA, USA.<br /><searchLink fieldCode="AU" term="%22Yang+WH%22">Yang WH</searchLink>; Ottawa Allergy Research Corporation, Department of Medicine, University of Ottawa, Ottawa, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Ritchie+B%22">Ritchie B</searchLink>; Division of Hematology, Department of Medicine, University of Alberta, Edmonton, AB, Canada.<br /><searchLink fieldCode="AU" term="%22Aygören-Pürsün+E%22">Aygören-Pürsün E</searchLink>; Department of Children and Adolescents, University Hospital Frankfurt, Goethe University, Frankfurt, Germany.<br /><searchLink fieldCode="AU" term="%22Keith+PK%22">Keith PK</searchLink>; McMaster University Medical Centre Site, Hamilton, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Busse+P%22">Busse P</searchLink>; Division of Clinical Immunology and Allergy, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Feuersenger+H%22">Feuersenger H</searchLink>; CSL Behring Innovation GmbH, Marburg, Germany.<br /><searchLink fieldCode="AU" term="%22Pawaskar+D%22">Pawaskar D</searchLink>; CSL Behring, King of Prussia, PA, USA; Janssen Research & Development LLC, Spring House, PA, USA.<br /><searchLink fieldCode="AU" term="%22Jacobs+I%22">Jacobs I</searchLink>; CSL Behring, King of Prussia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Pragst+I%22">Pragst I</searchLink>; CSL Behring Innovation GmbH, Marburg, Germany.<br /><searchLink fieldCode="AU" term="%22Doyle+MK%22">Doyle MK</searchLink>; CSL Behring, King of Prussia, PA, USA; Aro Biotherapeutics, Philadelphia, PA, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%222985213R%22">Lancet (London, England)</searchLink> [Lancet] 2022 Mar 05; Vol. 399 (10328), pp. 945-955. <i>Date of Electronic Publication: </i>2022 Feb 24.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>2985213R <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-547X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201406736%22">01406736 </searchLink><i>NLM ISO Abbreviation: </i>Lancet <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35219377
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S0140-6736(21)02225-X
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 945
    Titles:
      – TitleFull: Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Craig T
      – PersonEntity:
          Name:
            NameFull: Magerl M
      – PersonEntity:
          Name:
            NameFull: Levy DS
      – PersonEntity:
          Name:
            NameFull: Reshef A
      – PersonEntity:
          Name:
            NameFull: Lumry WR
      – PersonEntity:
          Name:
            NameFull: Martinez-Saguer I
      – PersonEntity:
          Name:
            NameFull: Jacobs JS
      – PersonEntity:
          Name:
            NameFull: Yang WH
      – PersonEntity:
          Name:
            NameFull: Ritchie B
      – PersonEntity:
          Name:
            NameFull: Aygören-Pürsün E
      – PersonEntity:
          Name:
            NameFull: Keith PK
      – PersonEntity:
          Name:
            NameFull: Busse P
      – PersonEntity:
          Name:
            NameFull: Feuersenger H
      – PersonEntity:
          Name:
            NameFull: Pawaskar D
      – PersonEntity:
          Name:
            NameFull: Jacobs I
      – PersonEntity:
          Name:
            NameFull: Pragst I
      – PersonEntity:
          Name:
            NameFull: Doyle MK
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 05
              M: 03
              Text: 2022 Mar 05
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1474-547X
          Numbering:
            – Type: volume
              Value: 399
            – Type: issue
              Value: 10328
          Titles:
            – TitleFull: Lancet (London, England)
              Type: main
ResultId 1